Hydrodynamic Cavitation in Pharmaceutical Particle Engineering, Crystallization, and Drug Delivery

11 Conclusions

Pharmaceutical particle engineering links molecular and interfacial properties with manufacturing performance and drug delivery. Particle size reduction can increase accessible surface area and dissolution, but it also creates interfacial energy and stability risk. Crystallization can create the required primary particle directly, but supersaturation, nucleation, growth, and post process aging must be controlled. Liposome production adds bilayer integrity, drug partitioning, encapsulation, leakage, and release to the particle size problem.

Controlled hydrodynamic cavitation provides a versatile mechanism for particle fracture, deagglomeration, micromixing, crystallization, and surface treatment. Microfluidizer processing is a related high pressure platform that uses fixed geometry microchannels, high shear, impact, cavitation, turbulence, and controlled pass exposure. The technologies should be described accurately and selected according to the mechanism that controls product quality. The supplied Microfluidics examples show substantial particle and vesicle size reductions in suspensions, emulsions, liposomes, and crystallization systems, while also showing that pass efficiency, pressure response, and stability are formulation dependent [1,17–27].

A successful commercial process is defined by a design space and control strategy, not by a single pressure setting. The process must control the full size distribution, morphology, solid state, surface properties, encapsulation, leakage, impurities, temperature, residence time, and equipment condition. Quality by Design, process analytical technology, orthogonal characterization, risk based validation, and lifecycle monitoring convert an intensive cavitation or mixing event into a reproducible pharmaceutical manufacturing operation [7–16,36–39].